Synaffix to Present Key ADC Technology Data on SYNtecan ETM Linker-Payload at World ADC Conference

Virtual poster presentation shows complete tumor regression and high tolerance of an ADC based on SYNtecan E ™

SYNtecan E ™ Linker-Payload is a potent exatecan-based DNA topoisomerase-1 inhibitor made by Synaffix. was developed

The data underscores the ability of Synaffix technologies to enable the best next-generation ADCs

AMSTERDAM, Oct 13, 2021 / PRNewswire / – Synaffix BV, a biotechnology company focused on commercializing its clinical-stage platform technology for developing antibody-drug conjugates (ADCs) with the best-in-class therapeutic index, will announce new data on its topoisomerase-1 -Inhibitor linker present- payload based on Exatecan (SYNtecan E ™), at the World ADC Conference At October 13, 2021:

Title: GlycoConnect ™ ADCs based on the topoisomerase-1 inhibitor exatecan (SYNtecan E ™) show excellent in-vivo efficacy and tolerability

Time: 9:30 p.m. CEST / 3:30 p.m. EDT / 12:30 p.m. PDT

Authors: Floris van Delft, Remon van Geel, Jorin Hoogenboom, Marloes Wijdeven, Laureen de Bever, Sorraya Popal, Jord van Schaik, Sander van Berkel

Synaffix uses GlycoConnect ™, a proprietary technology based on the native glycan monoclonal antibody and used as a privileged conjugation site for ADCs. In addition, a highly polar spacer technology (HydraSpace ™) enables the conjugation of any cytotoxic, hydrophobic payload and offers ADCs a significantly expanded therapeutic index (TI).

Camptothecins form a class of clinically relevant chemotherapeutic agents due to their ability to inhibit DNA topoisomerase 1 while showing excellent potential as a payload for antibody-drug conjugates (ADCs), as shown by the recent market approvals for Enhertu® and Trodelvy®.

Synaffix’s data shows that:

  • Exatecan, a clinically validated and potent campothecin, can be easily combined with Synaffix’s HydraSpace ™ technology, resulting in the SYNtecan E ™ linker payload

  • GlycoConnect ™ ADCs from trastuzumab were generated by conjugating SYNtecan E ™ to antibodies and tested for efficacy and tolerability

  • Complete tumor regression was observed in a mouse xenograft study (BT-474) after a single dose, while safety studies in mice confirmed the high tolerability of SYNtecan E ™ ADCs

Professor Doctor. Floris van Delft, CSO of Synaffix, said: “We are pleased to present new data on our groundbreaking technologies at this prestigious annual meeting. As the ADC community comes together again to share their latest research, Synaffix is excited to showcase its ongoing efforts to develop truly world-class ADC therapeutics. “

In the past few months Synaffix has signed major out-license agreements for ADC technology with Kyowa Kirin, a global specialty pharmaceutical company; ProfoundBio, an emerging oncology biotherapeutic company; and Innovent Biologics, a leading biopharmaceutical company developing innovative drugs to treat serious diseases. These come in addition to previous collaborations with ADC Therapeutics, Mersana Therapeutics and Shanghai Miracogen. Three ADCs using Synaffix technology are located in the clinic.

Notes for editors

About Synaffix BV

Synaffix BV is a biotechnology company enabling ADC product candidates at the clinical stage using its site-specific ADC technology platform. In addition to GlycoConnect ™ and HydraSpace ™ technology, the toxSYN ™ linker payload platform completes a fully complementary technology platform that enables any company with an antibody to add proprietary best-in-class ADC products under a single license from Synaffix to develop.

The Synaffix platform enables a fast timeline up to the clinic due to the established supply chain of technology components. Granted patents covering Synaffix’s technology offer end-to-end protection of manufacturing technology and the resulting products until at least 2035. Synaffix’s business model consists of target-specific out-licensing of technology, like the existing business with ADC. show Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin.

Synaffix is supported by a high-ranking European investor consortium with a focus on life sciences, which includes Aravis, BioGeneration Ventures, BOM Capital and M Ventures.

For more information, see the website at

Via Synaffix ADC platform technology

Synaffix’s proprietary ADC technology platform consists of GlycoConnect ™, HydraSpace ™ and toxSYN ™ technologies. Both GlycoConnect ™ and HydraSpace ™ are clinical-stage technologies that enable world-class ADCs with significantly improved efficacy and tolerability.

GlycoConnect ™ is a conjugation technology that uses the native antibody glycan for a site-specific and stable payload attachment and can be adapted to the formats DAR1, DAR2 or DAR4.

HydraSpace ™ is a compact and highly polar spacer technology that was developed to further improve the therapeutic index, especially for hydrophobic payloads. toxSYN ™ is a linker payload platform that includes key, validated MOAs for ADC product development, including SYNtecan E ™ and SYNeamicin G ™, among other linker payloads.

The combination of these three technologies offers developers a “one-stop” and easy-to-use ADC technology platform that enables every antibody developer to develop their own proprietary ADC and every ADC developer to further expand their pipeline and strengthen their competitive position.

At the World ADC US 2020 event, Synaffix won first place in the “Best ADC Platform Technology” category at the World ADC Awards, following a global technology review, peer-to-peer vote, and final independent evaluation Industry panel were experts. Synaffix is again on the short list for this prestigious award in 2021.



Show original content:

SOURCE Synaffix